Response to: 'The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region' by Rinaudo-Gaujous et al

Affiliations

¹ Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands.

Comment

K A van Schie et al. Ann Rheum Dis. 2015 Aug.

. 2015 Aug;74(8):e41.

doi: 10.1136/annrheumdis-2015-207529. Epub 2015 Apr 8.

¹ Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
² Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands.

No abstract available

Keywords: Anti-TNF; Inflammation; Treatment.

Comment on

The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.
van Schie KA, Hart MH, de Groot ER, Kruithof S, Aarden LA, Wolbink GJ, Rispens T. van Schie KA, et al. Ann Rheum Dis. 2015 Jan;74(1):311-4. doi: 10.1136/annrheumdis-2014-206237. Epub 2014 Oct 23. Ann Rheum Dis. 2015. PMID: 25342759
The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.
Rinaudo-Gaujous M, Roblin X, Marotte H, Paul S. Rinaudo-Gaujous M, et al. Ann Rheum Dis. 2015 Aug;74(8):e40. doi: 10.1136/annrheumdis-2015-207503. Epub 2015 Mar 23. Ann Rheum Dis. 2015. PMID: 25802246 No abstract available.